首页 > 最新文献

Cardiovascular Therapy and Prevention最新文献

英文 中文
Endovascular treatment of lead-related superior vena cava syndrome after pacemaker implantation 起搏器植入术后导联相关上腔静脉综合征的血管内治疗
Q3 Social Sciences Pub Date : 2024-02-08 DOI: 10.15829/1728-8800-2023-3850
D. Feshchenko, K. A. Kaperiz, B. A. Rudenko, F. B. Shukurov, D. Vasiliev, K. Davtyan, A. Tarasov, Е. A. Trufanova, M. T. Taliouridze
Superior vena cava syndrome (SVCS) is due to impaired venous outflow from the head, neck, limbs and upper half of the body into the right atrium due to stenosis or complete obstruction of the superior vena cava (SVC). Increased venous pressure in the SVC and lack of timely treatment leads not only to serious complications, but also to death. In recent years, the etiology of SVCS has changed dramatically, mainly due to an increase in the number of implanted intravascular devices (central venous catheters, pacemakers, defibrillators, and other devices). Endovascular methods have become widely used in the treatment of patients with SVCS. This was primarily due to the minimally invasive nature of the intervention, the high technical success of the operation and the rapid onset of clinical improvement. Patients who develop SVCS after device implantation are predominantly younger and have a longer life expectancy. When choosing a treatment method, it is extremely important to take these factors into account and give preference to methods providing a long-term effect with the fewest possible complications. The article presents a case of endovascular treatment of a patient with SVCS occlusion, which developed 9 years after pacemaker implantation, using intravascular imaging methods.
上腔静脉综合征(SVCS)是由于上腔静脉(SVC)狭窄或完全阻塞,导致从头部、颈部、四肢和上半身流入右心房的静脉流出受阻。上腔静脉内静脉压力增高和缺乏及时治疗不仅会导致严重的并发症,还会导致死亡。近年来,SVCS 的病因发生了巨大变化,主要原因是植入的血管内装置(中心静脉导管、心脏起搏器、除颤器和其他装置)数量增加。血管内方法已广泛用于治疗 SVCS 患者。这主要得益于介入治疗的微创性、手术的高技术成功率以及临床症状的迅速改善。植入装置后发生 SVCS 的患者主要比较年轻,预期寿命较长。在选择治疗方法时,考虑到这些因素并优先选择能产生长期疗效且并发症最少的方法极为重要。本文介绍了一例使用血管内成像方法对起搏器植入 9 年后出现的 SVCS 闭塞患者进行血管内治疗的病例。
{"title":"Endovascular treatment of lead-related superior vena cava syndrome after pacemaker implantation","authors":"D. Feshchenko, K. A. Kaperiz, B. A. Rudenko, F. B. Shukurov, D. Vasiliev, K. Davtyan, A. Tarasov, Е. A. Trufanova, M. T. Taliouridze","doi":"10.15829/1728-8800-2023-3850","DOIUrl":"https://doi.org/10.15829/1728-8800-2023-3850","url":null,"abstract":"Superior vena cava syndrome (SVCS) is due to impaired venous outflow from the head, neck, limbs and upper half of the body into the right atrium due to stenosis or complete obstruction of the superior vena cava (SVC). Increased venous pressure in the SVC and lack of timely treatment leads not only to serious complications, but also to death. In recent years, the etiology of SVCS has changed dramatically, mainly due to an increase in the number of implanted intravascular devices (central venous catheters, pacemakers, defibrillators, and other devices). Endovascular methods have become widely used in the treatment of patients with SVCS. This was primarily due to the minimally invasive nature of the intervention, the high technical success of the operation and the rapid onset of clinical improvement. Patients who develop SVCS after device implantation are predominantly younger and have a longer life expectancy. When choosing a treatment method, it is extremely important to take these factors into account and give preference to methods providing a long-term effect with the fewest possible complications. The article presents a case of endovascular treatment of a patient with SVCS occlusion, which developed 9 years after pacemaker implantation, using intravascular imaging methods.","PeriodicalId":9545,"journal":{"name":"Cardiovascular Therapy and Prevention","volume":" 18","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139792976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In memory of Professor Natalia V. Perova (08/12/1939 — 12/20/2023) 悼念纳塔利娅-佩罗娃教授 (08/12/1939 - 12/20/2023)
Q3 Social Sciences Pub Date : 2024-02-08 DOI: 10.15829/1728-8800-2023-3918
V. A. Metelskaya, M. N. Mamedov
.
.
{"title":"In memory of Professor Natalia V. Perova (08/12/1939 — 12/20/2023)","authors":"V. A. Metelskaya, M. N. Mamedov","doi":"10.15829/1728-8800-2023-3918","DOIUrl":"https://doi.org/10.15829/1728-8800-2023-3918","url":null,"abstract":"<jats:p>.</jats:p>","PeriodicalId":9545,"journal":{"name":"Cardiovascular Therapy and Prevention","volume":" 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139793148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex and gender differences in health and disease. Part II. Clinical and medical-social 健康与疾病中的性别差异。第二部分。临床与医疗社会
Q3 Social Sciences Pub Date : 2024-02-08 DOI: 10.15829/10.15829/1728-8800-2023-3831
O. Drapkina, O. T. Kim
An important condition for providing quality and safe care is to understand the differences between men and women in epidemiology, pathophysiology, risk factors, clinical performance of diseases, response to treatment and use of medical care. The first part of the review was devoted to the evolutionary mechanisms of differences in life expectancy and potential strategies for increasing life expectancy in men. The second part of the review examines sex and gender differences using the example of 3 groups of diseases, which, according to the World Health Organization, are the main causes of death in the European Region, in the programming of health and disease, as well as the reasons for the male-female health-survival paradox.
提供优质安全护理的一个重要条件是了解男女在流行病学、病理生理学、风险因素、疾病的临床表现、对治疗的反应和医疗护理的使用方面的差异。综述的第一部分专门讨论了预期寿命差异的进化机制以及延长男性预期寿命的潜在策略。综述的第二部分以 3 组疾病为例,研究了健康和疾病方案编制中的性和性别差异,根据世界卫生组织的资料,这 3 组疾病是欧洲地区死亡的主要原因,以及男女健康-生存悖论的原因。
{"title":"Sex and gender differences in health and disease. Part II. Clinical and medical-social","authors":"O. Drapkina, O. T. Kim","doi":"10.15829/10.15829/1728-8800-2023-3831","DOIUrl":"https://doi.org/10.15829/10.15829/1728-8800-2023-3831","url":null,"abstract":"An important condition for providing quality and safe care is to understand the differences between men and women in epidemiology, pathophysiology, risk factors, clinical performance of diseases, response to treatment and use of medical care. The first part of the review was devoted to the evolutionary mechanisms of differences in life expectancy and potential strategies for increasing life expectancy in men. The second part of the review examines sex and gender differences using the example of 3 groups of diseases, which, according to the World Health Organization, are the main causes of death in the European Region, in the programming of health and disease, as well as the reasons for the male-female health-survival paradox.","PeriodicalId":9545,"journal":{"name":"Cardiovascular Therapy and Prevention","volume":"16 S1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139793481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex and gender differences in health and disease. Part II. Clinical and medical-social 健康与疾病中的性别差异。第二部分。临床与医疗社会
Q3 Social Sciences Pub Date : 2024-02-08 DOI: 10.15829/10.15829/1728-8800-2023-3831
O. Drapkina, O. T. Kim
An important condition for providing quality and safe care is to understand the differences between men and women in epidemiology, pathophysiology, risk factors, clinical performance of diseases, response to treatment and use of medical care. The first part of the review was devoted to the evolutionary mechanisms of differences in life expectancy and potential strategies for increasing life expectancy in men. The second part of the review examines sex and gender differences using the example of 3 groups of diseases, which, according to the World Health Organization, are the main causes of death in the European Region, in the programming of health and disease, as well as the reasons for the male-female health-survival paradox.
提供优质安全护理的一个重要条件是了解男女在流行病学、病理生理学、风险因素、疾病的临床表现、对治疗的反应和医疗护理的使用方面的差异。综述的第一部分专门讨论了预期寿命差异的进化机制以及延长男性预期寿命的潜在策略。综述的第二部分以 3 组疾病为例,研究了健康和疾病方案编制中的性和性别差异,根据世界卫生组织的资料,这 3 组疾病是欧洲地区死亡的主要原因,以及男女健康-生存悖论的原因。
{"title":"Sex and gender differences in health and disease. Part II. Clinical and medical-social","authors":"O. Drapkina, O. T. Kim","doi":"10.15829/10.15829/1728-8800-2023-3831","DOIUrl":"https://doi.org/10.15829/10.15829/1728-8800-2023-3831","url":null,"abstract":"An important condition for providing quality and safe care is to understand the differences between men and women in epidemiology, pathophysiology, risk factors, clinical performance of diseases, response to treatment and use of medical care. The first part of the review was devoted to the evolutionary mechanisms of differences in life expectancy and potential strategies for increasing life expectancy in men. The second part of the review examines sex and gender differences using the example of 3 groups of diseases, which, according to the World Health Organization, are the main causes of death in the European Region, in the programming of health and disease, as well as the reasons for the male-female health-survival paradox.","PeriodicalId":9545,"journal":{"name":"Cardiovascular Therapy and Prevention","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139853329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of multimorbidity on the risk of events in men with chronic coronary artery disease after myocardial infarction and percutaneous coronary intervention 多病对慢性冠状动脉疾病男性患者在心肌梗死和经皮冠状动脉介入治疗后发生事件风险的影响
Q3 Social Sciences Pub Date : 2024-02-08 DOI: 10.15829/1728-8800-2023-3883
D. Dedov, V. P. Mazaev, A. N. Kovalchuk, A. Komkov, S. Ryazanova
Aim. To study the effect of multimorbidity on the risk of cardiovascular events (CVEs) in men with chronic coronary artery disease (CAD) after myocardial infarction (MI) and percutaneous coronary intervention (PCI).Material and methods. A total of 101 men with chronic CAD after MI and PCI were included in the study (mean age 60,5±6,1 years). Of these, taking into account the non-inclusion criteria and consent to examination, 2 following groups were formed: first (n=39) — men without CVEs; 2nd (n=39) — men with CVEs. In both groups, we studied the detection rate of grade I hypertension (HTN), class I obesity, hypercholesterolemia (HCE), and type 2 diabetes (T2D). The influence of HTN, obesity, HCE, and T2D on the risk of cardiovascular events was analyzed based on the calculation of contingency tables and Pearson's χ2, as well as odds ratios (OR) with 95,0% confidence intervals (CI). The follow-up period for patients averaged 3,6±0,5 years.Results. In men of group 2, compared with group 1 patients, grade I HTN, class I obesity, HCE were diagnosed more often in 1,3 (p=0,044), 1,4 (p=0,047), 1,2 (p=0,059) times, respectively. An increase in the risk of CVEs in men with chronic CAD, who underwent MI and PCI was associated with the detection of grade I HTN, class I obesity, HCE — OR 2,44 (CI: 1,88-6,75), OR 1,78 (CI: 1,56-4,62), OR 1,37 (CI: 1,11-4,17), respectively.Conclusion. Thus, the detection rate of grade I HTN, class I obesity and HCE in men with chronic CAD and CVEs at long-term follow-up after MI and PCI was significantly higher compared to patients with chronic CAD without CVEs after PCI. At the same time, the detection of grade I HTN, class I obesity and HCE were associated with an increased risk of cardiovascular events.
目的研究心肌梗死(MI)和经皮冠状动脉介入治疗(PCI)后患有慢性冠状动脉疾病(CAD)的男性中,多病对心血管事件(CVE)风险的影响。研究共纳入 101 名心肌梗死和经皮冠状动脉介入治疗后患有慢性冠状动脉疾病的男性(平均年龄为 60.5±6.1 岁)。其中,考虑到非纳入标准和同意检查的情况,分为以下两组:第一组(39 人)--无 CVE 的男性;第二组(39 人)--有 CVE 的男性。在这两组中,我们研究了 I 级高血压(HTN)、I 级肥胖、高胆固醇血症(HCE)和 2 型糖尿病(T2D)的检出率。高血压、肥胖、高胆固醇血症和 T2D 对心血管事件风险的影响是通过计算或然率表和 Pearson's χ2 以及带有 95.0% 置信区间 (CI) 的几率比 (OR) 进行分析的。患者的随访时间平均为 3.6±0.5 年。与第一组患者相比,第二组男性患者中,I级高血压、I级肥胖、HCE的诊断率分别为1.3(P=0.044)、1.4(P=0.047)、1.2(P=0.059)倍。接受心肌梗死和PCI手术的男性慢性CAD患者发生CVE的风险增加与I级高血压、I级肥胖和HCE的检出率有关,OR值分别为2,44(CI:1,88-6,75)、OR值分别为1,78(CI:1,56-4,62)、OR值分别为1,37(CI:1,11-4,17)。因此,在 MI 和 PCI 后的长期随访中,慢性 CAD 和 CVE 男性患者的 I 级高血压、I 级肥胖和 HCE 的检出率明显高于 PCI 后无 CVE 的慢性 CAD 患者。同时,I级高血压、I级肥胖和HCE的检出与心血管事件风险的增加有关。
{"title":"Influence of multimorbidity on the risk of events in men with chronic coronary artery disease after myocardial infarction and percutaneous coronary intervention","authors":"D. Dedov, V. P. Mazaev, A. N. Kovalchuk, A. Komkov, S. Ryazanova","doi":"10.15829/1728-8800-2023-3883","DOIUrl":"https://doi.org/10.15829/1728-8800-2023-3883","url":null,"abstract":"Aim. To study the effect of multimorbidity on the risk of cardiovascular events (CVEs) in men with chronic coronary artery disease (CAD) after myocardial infarction (MI) and percutaneous coronary intervention (PCI).Material and methods. A total of 101 men with chronic CAD after MI and PCI were included in the study (mean age 60,5±6,1 years). Of these, taking into account the non-inclusion criteria and consent to examination, 2 following groups were formed: first (n=39) — men without CVEs; 2nd (n=39) — men with CVEs. In both groups, we studied the detection rate of grade I hypertension (HTN), class I obesity, hypercholesterolemia (HCE), and type 2 diabetes (T2D). The influence of HTN, obesity, HCE, and T2D on the risk of cardiovascular events was analyzed based on the calculation of contingency tables and Pearson's χ2, as well as odds ratios (OR) with 95,0% confidence intervals (CI). The follow-up period for patients averaged 3,6±0,5 years.Results. In men of group 2, compared with group 1 patients, grade I HTN, class I obesity, HCE were diagnosed more often in 1,3 (p=0,044), 1,4 (p=0,047), 1,2 (p=0,059) times, respectively. An increase in the risk of CVEs in men with chronic CAD, who underwent MI and PCI was associated with the detection of grade I HTN, class I obesity, HCE — OR 2,44 (CI: 1,88-6,75), OR 1,78 (CI: 1,56-4,62), OR 1,37 (CI: 1,11-4,17), respectively.Conclusion. Thus, the detection rate of grade I HTN, class I obesity and HCE in men with chronic CAD and CVEs at long-term follow-up after MI and PCI was significantly higher compared to patients with chronic CAD without CVEs after PCI. At the same time, the detection of grade I HTN, class I obesity and HCE were associated with an increased risk of cardiovascular events.","PeriodicalId":9545,"journal":{"name":"Cardiovascular Therapy and Prevention","volume":"80 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139851145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severity and duration of immune response in people of different age categories after SARS-CoV-2 revaccination 不同年龄段人群接种 SARS-CoV-2 疫苗后免疫反应的严重程度和持续时间
Q3 Social Sciences Pub Date : 2024-02-08 DOI: 10.15829/1728-88002023-3870
O. Drapkina, S. Berns, M. G. Chashchin, A. Gorshkov, O. V. Zhdanova, L. N. Ryzhakova
The article discusses the effectiveness and safety of homologous and heterologous revaccination for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people of different age groups.Aim. The study the severity and duration of immune response in people of different age groups after SARS-CoV-2 revaccination.Material and methods. The study was carried out as part of the prospective registry Saturn, which included persons who received various SARS-CoV-2 revaccination regimens (homoand heterologous) based on the combination of two vaccines: Gam-COVID-Vac and Covivac. Group I (n=106) included persons who received a homologous revaccination with Gam-COVID-Vac, while group II (n=54) — heterologous revaccination with Gam-COVID-Vac and Covivac, group III (n=40) — homologous Covivac revaccination. In addition, all participants in the study were divided into two age categories: ≥60 years (n=33) and <60 years, (n=167). In all participants, the medical history was collected. At each visit, we assessed the quantitative level of specific IgG SARS-CoV-2 S-protein antibodies and plasma coagulation using the thrombodynamics method. At visits 1, 3 and 5, blood was collected to assess T-cell immunity activity (T-Spot.COVID test, Oxford Immunotec) to the SARS-CoV-2 virus.Results. Revaccination in persons ≥60 years of age ensures the intensity of humoral (quantitative level of specific IgG SARS-CoV-2 S-protein antibodies) and cellular immunity (quantitative assessment of SARS-CoV-2 spike protein-specific (panel A) and nucleocapsid-specific T-lymphocytes) comparable to that in younger individuals (<60 years). Revaccination did not increase the plasma thrombogenic potential in vaccinated people, regardless of age.Conclusion. In the group of vaccinated people ≥60 years old, an adequate humoral and cellular immune response was developed, which persisted for a year after revaccination, and even more intense cellular immunity was demonstrated compared to vaccinated people <60 years old. The plasma thrombogenic potential did not increase during vaccination and revaccination, regardless of age.
本文讨论了不同年龄段人群接种严重急性呼吸系统综合征冠状病毒 2 型(SARS-CoV-2)同源和异源疫苗的有效性和安全性。研究不同年龄组人群接种 SARS-CoV-2 疫苗后免疫反应的严重程度和持续时间。该研究是作为前瞻性登记土星的一部分进行的,其中包括接种了以两种疫苗组合为基础的各种 SARS-CoV-2 再接种方案(同种和异种)的人员:Gam-COVID-Vac 和 Covivac。第一组(106 人)包括接种 Gam-COVID-Vac 的同源再接种者,第二组(54 人)--接种 Gam-COVID-Vac 和 Covivac 的异源再接种者,第三组(40 人)--接种 Covivac 的同源再接种者。此外,研究中的所有参与者被分为两个年龄组:≥60 岁(33 人)和<60 岁(167 人)。我们收集了所有参与者的病史。每次就诊时,我们都会使用血栓动力学方法评估特异性 IgG SARS-CoV-2 S 蛋白抗体的定量水平和血浆凝固情况。在第 1 次、第 3 次和第 5 次就诊时,我们采集了血液以评估对 SARS-CoV-2 病毒的 T 细胞免疫活性(T-Spot.COVID 测试,牛津免疫技术公司)。对年龄≥60 岁的人重新接种疫苗可确保其体液免疫(特异性 IgG SARS-CoV-2 S 蛋白抗体的定量水平)和细胞免疫(SARS-CoV-2尖峰蛋白特异性(A 组)和核苷酸特异性 T 淋巴细胞的定量评估)的强度与年轻人(<60 岁)相当。再次接种疫苗不会增加接种者的血浆血栓形成潜能,与年龄无关。在接种过疫苗的≥60岁人群中,产生了充分的体液和细胞免疫反应,这种反应在再次接种后持续了一年,与接种过疫苗的<60岁人群相比,细胞免疫反应更加强烈。在接种和再次接种期间,血浆血栓形成潜能值并未增加,与年龄无关。
{"title":"Severity and duration of immune response in people of different age categories after SARS-CoV-2 revaccination","authors":"O. Drapkina, S. Berns, M. G. Chashchin, A. Gorshkov, O. V. Zhdanova, L. N. Ryzhakova","doi":"10.15829/1728-88002023-3870","DOIUrl":"https://doi.org/10.15829/1728-88002023-3870","url":null,"abstract":"The article discusses the effectiveness and safety of homologous and heterologous revaccination for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people of different age groups.Aim. The study the severity and duration of immune response in people of different age groups after SARS-CoV-2 revaccination.Material and methods. The study was carried out as part of the prospective registry Saturn, which included persons who received various SARS-CoV-2 revaccination regimens (homoand heterologous) based on the combination of two vaccines: Gam-COVID-Vac and Covivac. Group I (n=106) included persons who received a homologous revaccination with Gam-COVID-Vac, while group II (n=54) — heterologous revaccination with Gam-COVID-Vac and Covivac, group III (n=40) — homologous Covivac revaccination. In addition, all participants in the study were divided into two age categories: ≥60 years (n=33) and <60 years, (n=167). In all participants, the medical history was collected. At each visit, we assessed the quantitative level of specific IgG SARS-CoV-2 S-protein antibodies and plasma coagulation using the thrombodynamics method. At visits 1, 3 and 5, blood was collected to assess T-cell immunity activity (T-Spot.COVID test, Oxford Immunotec) to the SARS-CoV-2 virus.Results. Revaccination in persons ≥60 years of age ensures the intensity of humoral (quantitative level of specific IgG SARS-CoV-2 S-protein antibodies) and cellular immunity (quantitative assessment of SARS-CoV-2 spike protein-specific (panel A) and nucleocapsid-specific T-lymphocytes) comparable to that in younger individuals (<60 years). Revaccination did not increase the plasma thrombogenic potential in vaccinated people, regardless of age.Conclusion. In the group of vaccinated people ≥60 years old, an adequate humoral and cellular immune response was developed, which persisted for a year after revaccination, and even more intense cellular immunity was demonstrated compared to vaccinated people <60 years old. The plasma thrombogenic potential did not increase during vaccination and revaccination, regardless of age.","PeriodicalId":9545,"journal":{"name":"Cardiovascular Therapy and Prevention","volume":"26 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139852013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In memory of Academician of the Russian Academy of Sciences Leonid S. Barbarash (06/22/1941 — 11/14/2023) 纪念俄罗斯科学院院士列昂尼德-巴尔巴拉什(Leonid S. Barbarash)(1941 年 6 月 22 日 - 2023 年 11 月 14 日
Q3 Social Sciences Pub Date : 2024-02-08 DOI: 10.15829/1728-8800-2023-3880
A. Editorial
.
.
{"title":"In memory of Academician of the Russian Academy of Sciences Leonid S. Barbarash (06/22/1941 — 11/14/2023)","authors":"A. Editorial","doi":"10.15829/1728-8800-2023-3880","DOIUrl":"https://doi.org/10.15829/1728-8800-2023-3880","url":null,"abstract":"<jats:p>.</jats:p>","PeriodicalId":9545,"journal":{"name":"Cardiovascular Therapy and Prevention","volume":" 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139791133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In memory of Academician of the Russian Academy of Sciences Leonid S. Barbarash (06/22/1941 — 11/14/2023) 纪念俄罗斯科学院院士列昂尼德-巴尔巴拉什(Leonid S. Barbarash)(1941 年 6 月 22 日 - 2023 年 11 月 14 日
Q3 Social Sciences Pub Date : 2024-02-08 DOI: 10.15829/1728-8800-2023-3880
A. Editorial
.
.
{"title":"In memory of Academician of the Russian Academy of Sciences Leonid S. Barbarash (06/22/1941 — 11/14/2023)","authors":"A. Editorial","doi":"10.15829/1728-8800-2023-3880","DOIUrl":"https://doi.org/10.15829/1728-8800-2023-3880","url":null,"abstract":"<jats:p>.</jats:p>","PeriodicalId":9545,"journal":{"name":"Cardiovascular Therapy and Prevention","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139851281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Search and replication of associations of genome variants with lipid levels in a Russian sample 寻找并复制俄罗斯样本中基因组变异与血脂水平的关系
Q3 Social Sciences Pub Date : 2024-02-08 DOI: 10.15829/1728-8800-2023-3871
M. Zaichenoka, A. Ershova, A. Kiseleva, E. Sotnikova, Yu.V. Vyatkin, А. A. Zharikova, M. S. Pokrovskaya, S. Shalnova, V. Ramensky, A. N. Meshkov, O. Drapkina
Aim. To search associations for lipid profile parameters (lowand highdensity lipoprotein cholesterol levels, triglycerides and total cholesterol) in population samples from two Russian regions and make a replication analysis of a previously published genome-wide association study (GWA study, GWAS) for residents of three other Russian regions.Material and methods. The study included representative samples from the Vologda (n=689) and Ivanovo (n=1675) regions collected for the Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. We assessed lipid profile parameters and performed a targeted sequencing. A linear regression model adjusted for sex, age, and statin use was used to assess the associations of genomic variants with lipid profiles. The work replicated the results of a study by Usoltsev D, et al., 2023, carried out on population samples of individuals from St.Petersburg, Orenburg and Samara regions.Results. We identified variants for which associations with lipid parameters had previously been identified in a Russian sample. The proportion of replicated variants was 89% and 92% for the samples from the Vologda and Ivanovo regions, respectively. The directions of effects of all replicated variants in the previously published study (samples from the Orenburg and Samara regions and St. Petersburg) and in both studied samples (samples from the Ivanovo and Vologda regions) coincide.Conclusion. The results of the search for associations with lipid parameters in different Russian samples are consistent with each other.
研究目的在俄罗斯两个地区的人群样本中寻找血脂谱参数(低密度和高密度脂蛋白胆固醇水平、甘油三酯和总胆固醇)的关联,并对之前发表的针对俄罗斯其他三个地区居民的全基因组关联研究(GWA 研究,GWAS)进行复制分析。研究对象包括为俄罗斯联邦地区心血管疾病及其风险因素流行病学(ESSE-RF)研究收集的沃洛格达州(689 人)和伊万诺沃州(1675 人)的代表性样本。我们评估了血脂谱参数,并进行了靶向测序。采用线性回归模型对性别、年龄和他汀类药物使用情况进行调整,以评估基因组变异与血脂状况的关联。这项工作复制了乌索采夫 D 等人 2023 年对圣彼得堡、奥伦堡和萨马拉地区人口样本的研究结果。我们发现了以前在俄罗斯样本中发现的与血脂参数有关的变异。在沃洛格达州和伊万诺沃州的样本中,重复变异的比例分别为 89% 和 92%。在之前发表的研究(奥伦堡和萨马拉地区以及圣彼得堡的样本)中,以及在两项研究(伊万诺沃和沃洛格达地区的样本)中,所有重复变异体的影响方向都是一致的。在俄罗斯不同样本中寻找与血脂参数相关性的结果是一致的。
{"title":"Search and replication of associations of genome variants with lipid levels in a Russian sample","authors":"M. Zaichenoka, A. Ershova, A. Kiseleva, E. Sotnikova, Yu.V. Vyatkin, А. A. Zharikova, M. S. Pokrovskaya, S. Shalnova, V. Ramensky, A. N. Meshkov, O. Drapkina","doi":"10.15829/1728-8800-2023-3871","DOIUrl":"https://doi.org/10.15829/1728-8800-2023-3871","url":null,"abstract":"Aim. To search associations for lipid profile parameters (lowand highdensity lipoprotein cholesterol levels, triglycerides and total cholesterol) in population samples from two Russian regions and make a replication analysis of a previously published genome-wide association study (GWA study, GWAS) for residents of three other Russian regions.Material and methods. The study included representative samples from the Vologda (n=689) and Ivanovo (n=1675) regions collected for the Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. We assessed lipid profile parameters and performed a targeted sequencing. A linear regression model adjusted for sex, age, and statin use was used to assess the associations of genomic variants with lipid profiles. The work replicated the results of a study by Usoltsev D, et al., 2023, carried out on population samples of individuals from St.Petersburg, Orenburg and Samara regions.Results. We identified variants for which associations with lipid parameters had previously been identified in a Russian sample. The proportion of replicated variants was 89% and 92% for the samples from the Vologda and Ivanovo regions, respectively. The directions of effects of all replicated variants in the previously published study (samples from the Orenburg and Samara regions and St. Petersburg) and in both studied samples (samples from the Ivanovo and Vologda regions) coincide.Conclusion. The results of the search for associations with lipid parameters in different Russian samples are consistent with each other.","PeriodicalId":9545,"journal":{"name":"Cardiovascular Therapy and Prevention","volume":"24 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139852017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Search and replication of associations of genome variants with lipid levels in a Russian sample 寻找并复制俄罗斯样本中基因组变异与血脂水平的关系
Q3 Social Sciences Pub Date : 2024-02-08 DOI: 10.15829/1728-8800-2023-3871
M. Zaichenoka, A. Ershova, A. Kiseleva, E. Sotnikova, Yu.V. Vyatkin, А. A. Zharikova, M. S. Pokrovskaya, S. Shalnova, V. Ramensky, A. N. Meshkov, O. Drapkina
Aim. To search associations for lipid profile parameters (lowand highdensity lipoprotein cholesterol levels, triglycerides and total cholesterol) in population samples from two Russian regions and make a replication analysis of a previously published genome-wide association study (GWA study, GWAS) for residents of three other Russian regions.Material and methods. The study included representative samples from the Vologda (n=689) and Ivanovo (n=1675) regions collected for the Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. We assessed lipid profile parameters and performed a targeted sequencing. A linear regression model adjusted for sex, age, and statin use was used to assess the associations of genomic variants with lipid profiles. The work replicated the results of a study by Usoltsev D, et al., 2023, carried out on population samples of individuals from St.Petersburg, Orenburg and Samara regions.Results. We identified variants for which associations with lipid parameters had previously been identified in a Russian sample. The proportion of replicated variants was 89% and 92% for the samples from the Vologda and Ivanovo regions, respectively. The directions of effects of all replicated variants in the previously published study (samples from the Orenburg and Samara regions and St. Petersburg) and in both studied samples (samples from the Ivanovo and Vologda regions) coincide.Conclusion. The results of the search for associations with lipid parameters in different Russian samples are consistent with each other.
研究目的在俄罗斯两个地区的人群样本中寻找血脂谱参数(低密度和高密度脂蛋白胆固醇水平、甘油三酯和总胆固醇)的关联,并对之前发表的针对俄罗斯其他三个地区居民的全基因组关联研究(GWA 研究,GWAS)进行复制分析。研究对象包括为俄罗斯联邦地区心血管疾病及其风险因素流行病学(ESSE-RF)研究收集的沃洛格达州(689 人)和伊万诺沃州(1675 人)的代表性样本。我们评估了血脂谱参数,并进行了靶向测序。采用线性回归模型对性别、年龄和他汀类药物使用情况进行调整,以评估基因组变异与血脂状况的关联。这项工作复制了乌索采夫 D 等人 2023 年对圣彼得堡、奥伦堡和萨马拉地区人口样本的研究结果。我们发现了以前在俄罗斯样本中发现的与血脂参数有关的变异。在沃洛格达州和伊万诺沃州的样本中,重复变异的比例分别为 89% 和 92%。在之前发表的研究(奥伦堡和萨马拉地区以及圣彼得堡的样本)中,以及在两项研究(伊万诺沃和沃洛格达地区的样本)中,所有重复变异体的影响方向都是一致的。在俄罗斯不同样本中寻找与血脂参数相关性的结果是一致的。
{"title":"Search and replication of associations of genome variants with lipid levels in a Russian sample","authors":"M. Zaichenoka, A. Ershova, A. Kiseleva, E. Sotnikova, Yu.V. Vyatkin, А. A. Zharikova, M. S. Pokrovskaya, S. Shalnova, V. Ramensky, A. N. Meshkov, O. Drapkina","doi":"10.15829/1728-8800-2023-3871","DOIUrl":"https://doi.org/10.15829/1728-8800-2023-3871","url":null,"abstract":"Aim. To search associations for lipid profile parameters (lowand highdensity lipoprotein cholesterol levels, triglycerides and total cholesterol) in population samples from two Russian regions and make a replication analysis of a previously published genome-wide association study (GWA study, GWAS) for residents of three other Russian regions.Material and methods. The study included representative samples from the Vologda (n=689) and Ivanovo (n=1675) regions collected for the Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. We assessed lipid profile parameters and performed a targeted sequencing. A linear regression model adjusted for sex, age, and statin use was used to assess the associations of genomic variants with lipid profiles. The work replicated the results of a study by Usoltsev D, et al., 2023, carried out on population samples of individuals from St.Petersburg, Orenburg and Samara regions.Results. We identified variants for which associations with lipid parameters had previously been identified in a Russian sample. The proportion of replicated variants was 89% and 92% for the samples from the Vologda and Ivanovo regions, respectively. The directions of effects of all replicated variants in the previously published study (samples from the Orenburg and Samara regions and St. Petersburg) and in both studied samples (samples from the Ivanovo and Vologda regions) coincide.Conclusion. The results of the search for associations with lipid parameters in different Russian samples are consistent with each other.","PeriodicalId":9545,"journal":{"name":"Cardiovascular Therapy and Prevention","volume":" 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139792255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cardiovascular Therapy and Prevention
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1